Angiogenesis inhibitors in oncology. The research continues.
Philip
S
S
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania, USA.
D043925:Angiogenesis Inducing Agents / Q000037:antagonists & inhibitors; D020533:Angiogenesis Inhibitors / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors / Q000187:drug effects; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; D016228:Endothelial Growth Factors; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases